SIG 002
Alternative Names: SIG-002Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Sigilon Therapeutics
- Developer Eli Lilly and Company; Sigilon Therapeutics
- Class Induced pluripotent stem cell therapies
- Mechanism of Action Pancreatic beta cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (Implant)
- 14 Aug 2023 Sigilon Therapeutics has been acquired by Eli Lilly and Company
- 16 Mar 2023 Sigilon Therapeutics expects to initiate Investigational New Drug (IND)-enabling activities for Type 1 diabetes mellitus in 2023